Kiniksa Pharmaceuticals International, plc (KNSA) Stock Analysis and Metrics

Kiniksa Pharmaceuticals International

NASDAQ: KNSA

$62.86 ▼ -0.19 (-0.30%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap4.78 Bn

P/E53.57

P/S6.34

Div. Yield0.00

Revenue Growth (1y) (Qtr)55.51

Add ratio to table…

About

Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on developing and commercializing novel therapies for diseases with significant unmet medical need, particularly in cardiovascular indications. The company’s portfolio centers on interleukin-1 inhibition therapies targeting inflammatory pathways in autoinflammatory and cardiovascular diseases. Its lead product, ARCALYST, is an interleukin-1α and interleukin-1β cytokine trap approved for multiple indications in the United States.

The company generates revenue primarily through the commercial sale of ARCALYST in the United States for approved indications including recurrent pericarditis, Cryopyrin-Associated Periodic Syndromes (CAPS), and Deficiency of Interleukin-1 Receptor Antagonist (DIRA). Kiniksa evenly splits profits on ARCALYST sales with Regeneron under their licensing agreement and also shares proceeds from out-licensing arrangements, such as the agreement with Huadong for the Asia Pacific region. Revenue is derived from product sales, milestone payments, and royalty streams from collaborative and licensing partnerships.

The company operates through the following segments:

• ARCALYST: This segment includes the commercialization and development of ARCALYST, an interleukin-1α and interleukin-1β cytokine trap. ARCALYST is approved in the United States for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children 12 years and older, the treatment of CAPS including Familial Cold Autoinflammatory Syndrome and Muckle-Wells Syndrome in adults and children 12 years and older, and the maintenance of remission in DIRA in adults and children weighing 10 kg or more. The product is distributed through a select network of specialty pharmacies in the United States.

• KPL-387: This segment focuses on the development of an investigational fully human immunoglobulin G2 monoclonal antibody that binds interleukin-1 receptor 1, inhibiting IL-1α- and IL-1β-mediated signaling. KPL-387 is being developed for the treatment of recurrent pericarditis with the potential for monthly subcutaneous self-administration using a liquid formulation. The company is currently conducting the Phase 2 dose-focusing portion of a Phase 2/3 clinical trial, with data expected in the second half of 2026.

• KPL-1161: This segment involves the preclinical development of an Fc-modified immunoglobulin G2 monoclonal antibody designed as a modified version of KPL-387 to have an increased drug half-life, potentially supporting quarterly subcutaneous dosing. KPL-1161 binds IL-1R1 to inhibit IL-1α- and IL-1β-mediated signaling. The company plans to initiate a Phase 1 first-in-human clinical trial by the end of 2026.

• Abiprubart: This segment covers the development of an investigational monoclonal antibody inhibitor of CD40-CD154 costimulatory interaction. Kiniksa holds an exclusive worldwide license to abiprubart from Beth Israel Deaconess Medical Center. The company previously announced a Phase 2b clinical trial in Sjögren’s Disease but announced plans in February 2025 to discontinue development in that indication and explore strategic alternatives for the asset.

Kiniksa holds a differentiated position in the biopharmaceutical industry as the first and only company with an FDA-approved therapy for recurrent pericarditis through ARCALYST. The company faces competition from other interleukin-1 pathway inhibitors in development, including anakinra, canakinumab, lutikizumab, goflikicept, and VTX2735, but maintains a competitive advantage through its dual IL-1α and IL-1β inhibition mechanism, which addresses limitations of IL-1β-only inhibitors in certain patient populations. Its pipeline of next-generation IL-1 inhibitors aims to improve dosing convenience and patient experience.

The company’s customer base consists primarily of patients suffering from recurrent pericarditis, CAPS, and DIRA, who are treated by specialists including cardiologists, rheumatologists, and immunologists. Kiniksa serves patients through a specialty pharmacy network in the United States and collaborates with healthcare providers, patient advocacy groups, and institutions such as The Mayo Clinic and Johns Hopkins University on clinical research initiatives.

Investment Thesis

▲ Bull case

Kiniksa Pharmaceuticals has demonstrated sustained commercial momentum with ARCALYST that significantly outpaces market expectations, driven by structural shifts in prescribing behavior rather than temporary demand spikes. The company reported Q1 2026 ARCALYST revenue of $214.3 million, a 56% year-over-year increase, which was achieved despite industry-wide headwinds from co-pay resets and insurance plan changes. This growth stems from two durable commercial dynamics: an accelerated rate of new prescriber acquisition, with 400 new prescribers added in Q1 alone—representing the highest quarterly increase since launch—and a deepening of engagement through repeat prescribing, where over 1,320 prescribers now use ARCALYST multiple times. These metrics indicate that Kiniksa is successfully shifting the treatment paradigm in recurrent pericarditis from NSAIDs and colchicine to long-term IL-1 alpha and beta inhibition, as reinforced by the 2025 ACC Concise Clinical Guidance recommending ARCALYST as a preferred therapy. Crucially, with more than 25,000 healthcare professionals encountering recurrent pericarditis patients annually and less than 20% current penetration, the addressable market remains vastly underpenetrated. The company’s targeted DTC campaign, Heart’s Home, leverages AI and de-identified claims data to identify undiagnosed or undertreated patients, with early evidence showing that when patients initiate conversations about ARCALYST with providers, prescriptions occur in approximately 80% of cases. This highly efficient, low-waste approach to patient identification contrasts sharply with traditional broad-scale DTC efforts and suggests that Kiniksa can scale awareness without proportional increases in marketing spend. Furthermore, enhancements to the co-pay assistance program—including reduced maximum payouts and machine learning-driven identification of non-traditional payment plans—have improved gross-to-net trends without sacrificing patient access, indicating that profitability can improve even as volume grows. Kiniksa’s guidance raise to $930–$945 million in full-year 2026 revenue reflects confidence in these sustainable drivers, not just quarterly strength, and positions the company to continue capturing share in a market where standard of care is actively evolving in its favor.

Kiniksa Pharmaceuticals has demonstrated sustained commercial momentum with ARCALYST that significantly outpaces market expectations, driven by structural shifts in prescribing behavior rather than temporary demand spikes. The company reported Q1 2026 ARCALYST revenue of $214.3 million, a 56% year-over-year increase, which was achieved despite industry-wide headwinds from co-pay resets and insurance plan changes. This growth stems from two durable commercial dynamics: an accelerated rate of new prescriber acquisition, with 400 new prescribers added in Q1 alone—representing the highest quarterly increase since launch—and a deepening of engagement through repeat prescribing, where over 1,320 prescribers now use ARCALYST multiple times. These metrics indicate that Kiniksa is successfully shifting the treatment paradigm in recurrent pericarditis from NSAIDs and colchicine to long-term IL-1 alpha and beta inhibition, as reinforced by the 2025 ACC Concise Clinical Guidance recommending ARCALYST as a preferred therapy. Crucially, with more than 25,000 healthcare professionals encountering recurrent pericarditis patients annually and less than 20% current penetration, the addressable market remains vastly underpenetrated. The company’s targeted DTC campaign, Heart’s Home, leverages AI and de-identified claims data to identify undiagnosed or undertreated patients, with early evidence showing that when patients initiate conversations about ARCALYST with providers, prescriptions occur in approximately 80% of cases. This highly efficient, low-waste approach to patient identification contrasts sharply with traditional broad-scale DTC efforts and suggests that Kiniksa can scale awareness without proportional increases in marketing spend. Furthermore, enhancements to the co-pay assistance program—including reduced maximum payouts and machine learning-driven identification of non-traditional payment plans—have improved gross-to-net trends without sacrificing patient access, indicating that profitability can improve even as volume grows. Kiniksa’s guidance raise to $930–$945 million in full-year 2026 revenue reflects confidence in these sustainable drivers, not just quarterly strength, and positions the company to continue capturing share in a market where standard of care is actively evolving in its favor.

▼ Bear case

Despite Kiniksa’s strong quarterly performance, the company faces significant near-term risks tied to the execution and differentiation of its pipeline programs, particularly KPL-387, which could undermine long-term value creation if clinical timelines slip or regulatory expectations are not met. While management emphasized progress on KPL-387, including Phase II dose-focusing data expected in H2 2026 and Phase III initiation by year-end, they provided minimal detail on the actual dose levels being tested or the specific PK/PD thresholds that would define success, raising concerns about the robustness of the dose selection process. The Phase II study evaluates four dose levels in up to 20 patients per arm—a small sample size for a pivotal decision—and relies on historical rilonacept data as a benchmark, which may not fully translate to KPL-387’s longer-acting profile. More critically, the transition-to-monotherapy study uses a 16-week duration, which, while justified for achieving steady state, does not align with the 12- or 24-week assessment windows used in prior ARCALYST studies, potentially complicating cross-study comparisons and increasing uncertainty about real-world effectiveness during the critical switch period. Management acknowledged they have not yet disclosed the specific dose levels under evaluation, leaving investors without visibility into whether the therapeutic window is being adequately characterized. This opacity is compounded by the lack of clarity on KPL-1161, the Fc-modified IL-1 alpha and beta inhibitor targeting quarterly dosing, where the only disclosed milestone is a planned Phase I start by end-2026, with no data on preclinical potency, safety, or manufacturing scalability. Simultaneously, Kiniksa’s commercial strategy remains heavily reliant on ARCALYST, with over 90% of revenue derived from this single product, and while new prescriber growth is strong, the company has not addressed whether the current prescribing momentum can be sustained without escalating commercial spend. The DTC campaign, though innovative, is still in early stages, and there was no disclosure of customer acquisition cost, conversion funnel metrics, or break-even timelines, making it difficult to assess scalability. Furthermore, while gross-to-net improved in Q1 due to co-pay program changes, management conceded this was partly driven by one-time enhancements and expects a seasonal reversion later in the year, suggesting the benefit may not be structurally durable. With cash flow generation dependent on continued ARCALYST outperformance and pipeline spending set to rise as KPL-387 advances into Phase III and KPL-1161 enters clinical testing, any delay in clinical readouts or unfavorable efficacy/safety signals could force a abrupt shift from investment to preservation mode, undermining the premium valuation implied by the current guidance raise.

Despite Kiniksa’s strong quarterly performance, the company faces significant near-term risks tied to the execution and differentiation of its pipeline programs, particularly KPL-387, which could undermine long-term value creation if clinical timelines slip or regulatory expectations are not met. While management emphasized progress on KPL-387, including Phase II dose-focusing data expected in H2 2026 and Phase III initiation by year-end, they provided minimal detail on the actual dose levels being tested or the specific PK/PD thresholds that would define success, raising concerns about the robustness of the dose selection process. The Phase II study evaluates four dose levels in up to 20 patients per arm—a small sample size for a pivotal decision—and relies on historical rilonacept data as a benchmark, which may not fully translate to KPL-387’s longer-acting profile. More critically, the transition-to-monotherapy study uses a 16-week duration, which, while justified for achieving steady state, does not align with the 12- or 24-week assessment windows used in prior ARCALYST studies, potentially complicating cross-study comparisons and increasing uncertainty about real-world effectiveness during the critical switch period. Management acknowledged they have not yet disclosed the specific dose levels under evaluation, leaving investors without visibility into whether the therapeutic window is being adequately characterized. This opacity is compounded by the lack of clarity on KPL-1161, the Fc-modified IL-1 alpha and beta inhibitor targeting quarterly dosing, where the only disclosed milestone is a planned Phase I start by end-2026, with no data on preclinical potency, safety, or manufacturing scalability. Simultaneously, Kiniksa’s commercial strategy remains heavily reliant on ARCALYST, with over 90% of revenue derived from this single product, and while new prescriber growth is strong, the company has not addressed whether the current prescribing momentum can be sustained without escalating commercial spend. The DTC campaign, though innovative, is still in early stages, and there was no disclosure of customer acquisition cost, conversion funnel metrics, or break-even timelines, making it difficult to assess scalability. Furthermore, while gross-to-net improved in Q1 due to co-pay program changes, management conceded this was partly driven by one-time enhancements and expects a seasonal reversion later in the year, suggesting the benefit may not be structurally durable. With cash flow generation dependent on continued ARCALYST outperformance and pipeline spending set to rise as KPL-387 advances into Phase III and KPL-1161 enters clinical testing, any delay in clinical readouts or unfavorable efficacy/safety signals could force a abrupt shift from investment to preservation mode, undermining the premium valuation implied by the current guidance raise.

Peer Comparison

Companies in the Drug Manufacturers - Specialty & Generic

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HLN	Haleon plc	88.07 Bn	103.29	6.00	11.45 Bn
2	TEVA	Teva Pharmaceutical Industries Ltd	35.75 Bn	23.02	2.06	16.63 Bn
3	ZTS	Zoetis Inc.	31.84 Bn	12.05	3.35	9.05 Bn
4	TAK	Takeda Pharmaceutical Co Ltd	27.18 Bn	-10.29	0.59	28.76 Bn
5	UTHR	UNITED THERAPEUTICS Corp	23.09 Bn	17.93	7.28	-
6	RDHL	RedHill Biopharma Ltd.	21.32 Bn	2,931.66	2.24	-
7	VTRS	Viatris Inc	19.96 Bn	-67.32	1.37	14.34 Bn
8	NBIX	Neurocrine Biosciences Inc	17.66 Bn	26.41	5.69	-

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password